Greysun is the lead guides editor at Game Rant, covering all the biggest AAA titles to the smaller indie gems. He's been a big Nintendo fan since the SNES days and patiently awaits a Super Mario ...

YouTube TV and ESPN both refuse to budge as the ongoing dispute and channel blackout approaches two full weeks, but customers can alleviate some frustration with alternative streaming services that ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

Popular culture often distorts autonomy into science fiction caricatures. This framing obscures the real challenges and opportunities facing the U.S. military: autonomy as a layered, incremental ...

Bleach is one of many action anime with a power system revolving around characters taking on transformations to fight. Naturally, the Shikai and Bankai of the Soul Reapers are the most common examples ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. JOURNAVX drives revenue with strong acute pain demand ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Things weren’t going right for the Miami Hurricanes early on Saturday night against the Stanford Cardinal. Their first three offensive drives stalled out, ending with a missed field goal, a punt and a ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...

Vertex Pharmaceuticals plans by year-end to submit part of a license application to regulators for its kidney-disease treatment, and to have the full application submitted by first half of next year.

Syracuse, N.Y. — Hundreds of dollars in overdraft and late fees. Calling in sick because there’s not enough money to get gas for the car or pay for a rideshare. Borrowing from family members to get ...